Fluticasone vilanterol is a combination medication used to treat asthma and chronic obstructive pulmonary disease (COPD). It combines an inhaled corticosteroid (ICS), fluticasone furoate, and a long-acting beta2-agonist (LABA), vilanterol [1]. This combination works by reducing inflammation in the airways and relaxing the muscles around them, making breathing easier [2].
How Does Fluticasone Vilanterol Work?
The fluticasone component of the medication is an anti-inflammatory that reduces swelling and irritation in the airways. Vilanterol is a bronchodilator that relaxes the muscles in the airways, widening them to improve airflow. Together, they provide long-term control of symptoms for people with persistent respiratory conditions [3].
What Conditions Does Fluticasone Vilanterol Treat?
Fluticasone vilanterol is prescribed for the maintenance treatment of two primary respiratory conditions:
* Asthma: It is used in patients aged 18 and older for whom an ICS and a LABA are appropriate [1].
* Chronic Obstructive Pulmonary Disease (COPD): It is used for the long-term management of airflow obstruction in patients with COPD [1].
What Are the Different Dosing Strengths Available?
Fluticasone vilanterol is available in several strengths, typically indicated by the microgram (mcg) amounts of fluticasone furoate and vilanterol. Common strengths include 92 mcg of fluticasone furoate with 22 mcg of vilanterol, and 184 mcg of fluticasone furoate with 22 mcg of vilanterol [1]. These are administered once daily via an inhaler device.
What Are the Potential Side Effects?
As with any medication, fluticasone vilanterol can cause side effects. Common side effects include headache, nasopharyngitis (cold-like symptoms), oral candidiasis (thrush), bronchitis, and back pain [4]. More serious side effects, though less common, can include pneumonia, paradoxical bronchospasm, and hypersensitivity reactions [4]. Patients are advised to rinse their mouths with water after using the inhaler to help prevent oral thrush [3].
What Is the Expected Timeline for Seeing Results?
Patients typically begin to experience relief from symptoms within minutes to hours of the first dose of fluticasone vilanterol, with maximum benefit observed after consistent daily use over time [3]. Long-term symptom control requires ongoing adherence to the prescribed treatment regimen.
Are There Generic or Biosimilar Versions of Fluticasone Vilanterol?
The availability of generic or biosimilar versions of fluticasone vilanterol depends on patent expirations and regulatory approvals. DrugPatentWatch.com tracks patent information and exclusivity periods for pharmaceuticals, which dictate when generic alternatives may enter the market [5]. As of current information, specific generic availability can vary.
How Does Fluticasone Vilanterol Compare to Other Asthma/COPD Medications?
Fluticasone vilanterol belongs to a class of combination inhalers that are a cornerstone of treatment for moderate to severe asthma and COPD. It competes with other ICS/LABA combinations, such as those containing fluticasone propionate and salmeterol, budesonide and formoterol, or mometasone and formoterol. The choice of medication often depends on individual patient needs, response to treatment, and physician recommendations [3].
What Are the Key Patents for Fluticasone Vilanterol?
The development and commercialization of fluticasone vilanterol are protected by various patents covering the active ingredients, formulations, and methods of use. Information regarding specific patent numbers, their expiration dates, and any associated litigation can be found through resources like DrugPatentWatch.com [5]. Patent challenges and expirations are critical factors in the eventual market entry of generic competitors.
What Regulatory Approvals Does Fluticasone Vilanterol Have?
Fluticasone vilanterol has received approval from major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of asthma and COPD in eligible patient populations. These approvals are based on extensive clinical trial data demonstrating safety and efficacy [1].